BackAlzamend Neuro Overview

Alzamend Neuro Receivables

Latest receivables for ALZN: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Alzamend Neuro Receivables History

Loading

Alzamend Neuro vs. peers: Receivables Comparison

Loading

Alzamend Neuro Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Alzamend Neuro (ALZN) FAQ

The latest receivables for ALZN is $0 as of April 2026. Investors often review this figure alongside Alzamend Neuro's historical trend and sector peers before judging valuation or financial health.

A receivables figure of $0 for ALZN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ALZN's receivables ($0), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Alzamend Neuro's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.